Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1645 1792
This examiner grants 54% of resolved cases
Robert A. Zeman examines cases in Art Unit 1645 of Tech Center 1700. He has 787 resolved cases and an allowance rate of 54.3 percent. This 54.3 percent rate indicates a prosecution environment where success is achievable. The median days to allowance is 1342. This 1342-day figure is a metric for managing client expectations. Practitioners should factor this timeline into their overall strategy in Tech Center 1700.
The interview lift is 27.7 percent. This 27.7 percent lift suggests that interviews are productive. This increase can improve the likelihood of a grant and should be a tool for practitioners. With 787 resolved cases, the 54.3 percent allowance rate is a baseline for Art Unit 1645. The 27.7 percent lift indicates that the examiner is receptive to resolving issues through discussion. The 1342-day median is a specific point of reference for the duration of the prosecution phase.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18531938 | METHOD TO PROVIDE LONG-LASTING CLEANING | Final Rejection | The Procter & Gamble Company |
| 18266625 | MICROORGANISM THAT PRODUCES USEFUL SUBSTANCE AND METHOD FOR PRODUCING USEFUL SUBSTANCE | Final Rejection | KANEKA CORPORATION |
| 18872768 | STAPHYLOCOCCUS AUREUS VACCINE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18826610 | ENGINEERED BACTERIAL RIBOSOME COMPOSITIONS AND METHODS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18322442 | METHODS FOR DIAGNOSING GASTRIC INTESTINAL METAPLASIA | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18011008 | ADAS COMPRISING BACTERIAL SECRETION SYSTEMS | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18270611 | METHODS AND COMPOSITION FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Final Rejection | The General Hospital Corporation |
| 17924064 | Methods for Verification of Drug Levels Using Dried Blood Samples | Non-Final OA | Sanofi |
| 18873753 | VACCINE FOR PROTECTION AGAINST LEPTOSPIRA SEROVAR ICTEROHAEMORRHAGIAE | Non-Final OA | INTERVET INC. |
| 17641031 | COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION | Final Rejection | INTERVET INC. |
| 17750968 | VACCINE AND METHODS FOR DETECTING AND PREVENTING FILARIASIS | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17768766 | SHIGELLA MULTI-EPITOPE FUSION ANTIGEN PROTEINS AND METHODS OF USE | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18696298 | EFFECT OF A PROBIOTIC COMPOSITION ON VAGINAL LACTOBACILLUS SPECIES | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18566194 | BACTERIAL STRAINS FOR USE IN PREVENTING, TREATING AND/OR REDUCING SYMPTOMS ASSOCIATED WITH A RHINOVIRUS-INDUCED COLD INFECTION | Final Rejection | International N&H Denmark APS |
| 17601051 | MULTIVALENT VACCINES DERIVED FROM KLEBSIELLA OUTER MEMBRANE PROTEINS | Non-Final OA | University of Pittsburgh-Of the Commonwealth System of Higher Education |
| 18799550 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | Non-Final OA | CHILDREN'S MEDICAL CENTER CORPORATION |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | Non-Final OA | Evaxion Biotech A/S |
| 18008797 | METHOD OF INCREASING NISIN PRODUCTION IN LACTOCOCCUS LACTIS | Non-Final OA | Chr. Hansen A/S |
| 16331863 | THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS | Final Rejection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18438870 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18694118 | Methods of Inhibiting Diseases Caused by Respiratory Viruses | Non-Final OA | BiomEdit, LLC |
| 18577867 | CORYNEBACTERIUM STRAINS FOR USE IN THE PREVENTION OF A VIRAL INFECTION | Non-Final OA | SEMMELWEIS EGYETEM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy